BALAXI

Balaxi Pharmaceuticals financials

Market cap
₹129 Cr
Sector
Healthcare

What Balaxi Pharmaceuticals Limited does

Balaxi Pharmaceuticals sources essential medicines - a mix of generics and branded generics - from WHO GMP-certified contract manufacturers in India, China and Portugal, then registers, brands and distributes them in frontier markets across Latin America (Guatemala, Dominican Republic, Honduras, El Salvador, Nicaragua) and Africa (Angola, Central African Republic) under a 'produce, stock and sell' model. Products reach patients through a network of 38 warehouses and an on-ground distribution fleet, backed by a portfolio of 964 product registrations across seven countries. The company is backward-integrating with its first own pharmaceutical formulation facility (General Oral Solid Dosage forms) at a Pharma SEZ in Jadcherla, Hyderabad, and is discontinuing an ancillary Building Hardware business to focus solely on pharmaceuticals.

Segments

  • Africa distribution
  • Latin America distribution
  • Pharmaceutical manufacturing
  • Building Hardware
Product registrations
964 across 7 countries
Countries of operation
7 (Guatemala, Dominican Republic, Angola, Honduras, El Salvador, Nicaragua, Central African Republic)
Warehouses
38, with on-ground logistics fleet
Manufacturing facility
1 (Pharma SEZ, Jadcherla, Hyderabad) - General Oral Solid Dosage formulations
Overseas subsidiaries
7 wholly-owned (Dubai, Guatemala, Dominican Republic, Angola, El Salvador, Honduras, Nicaragua)
Contract manufacturing sourcing
WHO GMP-certified plants in India, China and Portugal
Founded 2003Headquarters Hyderabad, Telangana, India Company website

Quarterly results

Q1 FY27: revenue up 14.1%, net profit up 348.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue77 73 76 71 56 −27%73 −1%71 −7%81 +14%
EBITDA11 4 13 4 1 −89%3 −23%0 −99%5 +12%
Net profit5 5 9 0 0 −95%0 −94%1 −93%1 +348%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −48.6% 1Y

₹20.0₹30.0₹40.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹45.48 on 10 Sept 2025 → ₹23.39. High ₹47.01 (22 Sept 2025), low ₹15.67 (30 Mar 2026).

Financials, as filed

Revenue fell 7.0% a year over 3 years, FY23 to FY26. Operating margin narrowed to 3.2%.

Year endingFY23FY24FY25FY26
Revenue₹336 Cr₹241 Cr₹293 Cr₹270 Cr
Operating profit₹57 Cr₹47 Cr₹37 Cr₹9 Cr
Operating margin16.8%19.4%12.7%3.2%
Interest₹1 Cr₹2 Cr₹3 Cr₹4 Cr
Depreciation₹2 Cr₹2 Cr₹2 Cr₹2 Cr
Net profit₹46 Cr₹-2 Cr₹25 Cr₹1 Cr
Net margin13.7%-1.0%8.6%0.5%
Cash from operations₹6 Cr₹5 Cr₹-35 Cr₹-4 Cr
Free cash flow₹-9 Cr₹4 Cr₹-57 Cr₹-25 Cr
ROCE37.0%21.0%13.0%3.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹10 Cr₹10 Cr₹10 Cr₹11 Cr₹11 Cr₹11 Cr
Reserves₹55 Cr₹103 Cr₹173 Cr₹190 Cr₹227 Cr₹238 Cr
Borrowings₹4 Cr₹4 Cr₹13 Cr₹19 Cr₹57 Cr₹58 Cr
Other liabilities₹31 Cr₹60 Cr₹43 Cr₹38 Cr₹28 Cr₹30 Cr
Total liabilities₹100 Cr₹176 Cr₹240 Cr₹258 Cr₹322 Cr₹337 Cr
Fixed assets₹2 Cr₹29 Cr₹41 Cr₹41 Cr₹45 Cr₹82 Cr
Capital work in progress₹0 Cr₹1 Cr₹3 Cr₹2 Cr₹34 Cr₹0 Cr
Investments₹3 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹94 Cr₹147 Cr₹195 Cr₹215 Cr₹244 Cr₹255 Cr
Total assets₹100 Cr₹176 Cr₹240 Cr₹258 Cr₹322 Cr₹337 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, FIIs trimmed −8.87 pp while the public added +6.33 pp. The shareholder count grew 7% to 14,682.

Promoters
66.0%
DIIs
2.6%
Public
31.4%

Since Jun 2025

  • FIIs −8.87 pp
  • Public +6.33 pp
  • DIIs +2.54 pp

How it drifted, 12 quarters

Over this window the public went from 10.2% to 31.4% — +21.3 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 71.2%, FIIs 18.6%, DIIs 0.0%, Public 10.2%.Dec '23: Promoters 71.2%, FIIs 18.6%, DIIs 0.0%, Public 10.2%.Mar '24: Promoters 66.9%, FIIs 17.2%, DIIs 0.0%, Public 15.9%.Jun '24: Promoters 66.0%, FIIs 16.9%, DIIs 0.0%, Public 17.1%.Sep '24: Promoters 66.0%, FIIs 16.5%, DIIs 0.0%, Public 17.5%.Dec '24: Promoters 66.0%, FIIs 16.5%, DIIs 0.0%, Public 17.5%.Mar '25: Promoters 66.0%, FIIs 16.0%, DIIs 0.0%, Public 18.0%.Jun '25: Promoters 66.0%, FIIs 8.9%, DIIs 0.0%, Public 25.1%.Sep '25: Promoters 66.0%, FIIs 3.5%, DIIs 0.0%, Public 30.5%.Dec '25: Promoters 66.0%, FIIs 1.7%, DIIs 0.0%, Public 32.2%.Mar '26: Promoters 66.0%, DIIs 2.6%, Public 31.4%.Jun '26: Promoters 66.0%, DIIs 2.6%, Public 31.4%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Balaxi Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Balaxi Overseas Private Limited 63.40%unchanged
Rgsl Investment Fund - Rgsl Investment Lvf 1 AIF2.54%unchanged
Kunal Mahendra Bhakta 1.86%unchanged
Ashish Maheshwari 1.64%unchanged
Key Managerial Personnel 1.41%unchanged
Amol Anand Mantri 1.41%unchanged
P P Zibi Jose 1.29%unchanged
Minoshi Maheshwari 0.96%unchanged
Investor Education and Protection Fund (IEPF) 0.70%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Balaxi Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.